KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash from Operations (2016 - 2026)

Gsk has reported Cash from Operations over the past 18 years, most recently at 1820040839.39 for Q1 2026.

  • For Q1 2026, Cash from Operations rose 11.07% year-over-year to 1820040839.39; the TTM value through Mar 2026 reached 10644601886.47, up 20.53%, while the annual FY2025 figure was 10296816542.34, 22.41% up from the prior year.
  • Cash from Operations for Q1 2026 was 1820040839.39 at Gsk, down from 3030118600.11 in the prior quarter.
  • Over five years, Cash from Operations peaked at 3966721425.69 in Q4 2023 and troughed at 348851232.01 in Q1 2023.
  • A 5-year average of 2414875645.96 and a median of 2798692558.89 in 2024 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: soared 451.63% in 2022 and later plummeted 90.56% in 2023.
  • Year by year, Cash from Operations stood at 2868982673.51 in 2022, then skyrocketed by 38.26% to 3966721425.69 in 2023, then fell by 24.64% to 2989275783.94 in 2024, then increased by 1.37% to 3030118600.11 in 2025, then plummeted by 39.93% to 1820040839.39 in 2026.
  • Business Quant data shows Cash from Operations for GSK at 1820040839.39 in Q1 2026, 3030118600.11 in Q4 2025, and 2998282692.11 in Q3 2025.